RDGL Vivos Inc

$RDGL RDGL at $0.0487 is only about a $24M market cap. That's the number investors should focus on. This isn't a company starting from zero. IsoPet: 200+ animal treatments. India: human clinical experience. PrecisionGel: continued platform development. FDA: IDE approved for the Mayo feasibility study. Now RDGL is moving toward the next major milestone: U.S. human treatment at Mayo. IRB ? First Patient ? Clinical Data ? Validation So look at where RDGL is today versus where the company is heading. A company with years of development, real-world IsoPet experience, international human experience, FDA authorization for U.S. clinical testing, and Mayo ahead is currently valued at only ~$24M. That's the disconnect. If Mayo produces positive clinical data, RDGL will have a very different set of facts for the market to value. At $0.0487, the current valuation looks extremely small relative to the milestones and potential ahead.

$RDGL is kinda wild if you think about it. Same gel. RadioGel for humans. IsoPet for animals. Two markets, one platform. Take the Yttrium-90 out you get PrecisionGel. Add proteins or other drugs and it turns into a completely different device for immunotherapy or local chemo or pain or dozen other treatments. That potential is hard to ignore.

$RDGL Is anyone talking about the 1 million Series D shares? The key wording is that each Series D holder is entitled to “the equivalent of fifty votes for every share of Common Stock issuable upon conversion” of their Series D. At the initial conversion price, $1.00 ÷ $0.08 = 12.5 common shares per Series D share. Therefore, 12.5 × 50 = 625 votes for each Series D share while it remains Series D. So 1 million Series D shares would indeed carry 625 million votes if all 1 million were issued and outstanding. If converted, those 1 million preferred shares would become 12.5 million common shares, which would carry 12.5 million ordinary common-stock votes. This is a huge voting control. Who are they doing this for? I feel like it's got to be someone important to give this kind of voting control.

$RDGL - I think the next 5-6 months are interesting. November/December: Expecting the Mayo IRB submission now that site assessment is underway. Mexico also has another meeting in November, so I wouldn’t be surprised to see a hospital partnership announced by December or January. INCan is one possibility, but nothing is confirmed. December/January: The India manufacturing facility could potentially be completed, opening the door for international distribution. This is where Saudi Arabia gets interesting. Salam’s veterinary facilities in Buraidah, Qassim, could be a great fit for IsoPet. Nothing is confirmed, but the potential market is significant. December/February: Expecting the paper on the first 10 human patients to move forward, along with India’s Phase 1 application. I would assume they may wait for the paper before applying for Phase 1 trials in additional countries, including Saudi Arabia if a partnership is established, as well as pursuing a fast-track application in Mexico.

$RDGL’s unnamed Mexican partner may be Mexico City’s National Cancer Institute (INCan), though Vivos hasn’t confirmed it. Its national referral role, nuclear medicine, radiation oncology and research capabilities make it a plausible fit. If confirmed, its infrastructure could support patient selection, image-guided injection, dosimetry and follow-up, potentially expanding RadioGel studies beyond thyroid cancer. Site readiness still needs verification. After November’s follow-up, an agreement and protocol could follow in Q1 2027. My earliest plausible first-treatment estimate is Q3 2027; Q4 is more realistic, subject to approvals, training, logistics and enrollment.

$RDGL lastly, MOM the team keeps buying into the company and increasing their own holdings. To me it’s quite indicative that they have faith in their own company’s growth.

$RDGL when will they scale isopet and start selling it for a profit? How many years will that take?

$RDGL For an Early Feasibility Study (EFS) / First-in-Human study involving a Class III high-risk combination device like RadioGel® (an injectable Yttrium-90 therapeutic radioisotope), institutional review typically takes 1 to 3 months (4 to 12 weeks) from formal submission to final sign-off.

$RDGL it feels like this company diversifies in so much to look good from a shareholders perspective yet makes very little progress on any of the major goals… starting to lose a lot of confidence here, this is starting to smell like a typical otc… I have been here for years giving them the benefit of the doubt but they continue to not deliver…

$RDGL for those who think the FDA only approved the IDE with “conditions” and did not approve with full “standard” approval, think again. Don’t listen to the bashers and manipulators who are trying to screw you and with their attempts to manipulate and slander this stock ….

$RDGL CEO knew the company potential huge purchase at .50c check out $TIPS ceo just sold $NXGB and cancel 2N shares

$RDGL where in the world is an update on moving forward with an EFS, the goalposts always move for human therapy and it’s the same non sense everytime… smh

$RDGL I know that some members on RDGL ihub are aware the "phony investor" that is. Equal mention must be made of . Don't let the "Oscar performance" he's putting forward on IHUB fool you. The character is the face behind , , , $$$. Make no mistake that is one of the principal actors working tirelessly (behind the scenes) against vivos stock while he fronts on ihub as an investor whose heart and money is firmly on vivos and radiogel side. The actor posted long ago under about the current price range and how it would be engineered. Do a deep diving into his abandoned handle that was active from 2023 -April 2026. The deceiful poster is consistent on abandoning handles that attract attention to his devious schemes. In addition to that, the handle also was a crusader for rs at pennies range and uplisting to the exchanges and we know how that works out well, LOL!